个人简历

陆小云，博士研究生，研究员，博士生导师，国家优秀青年基金获得者。2005年6月毕业于中国药科大学制药工程专业，获学士学位，2010年6月毕业于中国药科大学药物化学专业，获理学博士学位，2010年7月-2016年2月在中国科学院广州生物医药与健康研究院从事科研工作，2016年3月加入暨南大学药学院，从事教学科研工作。

研究领域

""（1）新型激酶抑制剂的发现研究\r
（2）诱导耐药突变激酶抑制剂的发现研究\r
（3）激酶抑制剂的计算设计方法研究""""

近期论文

Zuqin Wang#, Jie Wang#, Yongjin Wang#, Shuang Xiang , Xiaojuan Song , Zhengchao Tu , Yang Zhou, Zhi-Min Zhang*, Zhang Zhang*, Ke Ding*, Xiaoyun Lu*.Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance. J. Med. Chem. 2022,10.1021/acs.jmedchem.2c00308.\r
\r
Hao Chen#, Mengzhen Lai #, Tao Zhang, Yuqing Chen, Linjiang Tong, Sujie Zhu , Yang Zhou, Xiaomei Ren, Jian Ding, Hua Xie*, Xiaoyun Lu *, Ke Ding*. Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. J. Med. Chem. 2022, doi: 10.1021/acs.jmedchem.2c00168.\r
\r
Min Shao#, Xiaojuan Chen,# Fang Yang, Xiaojuan Song, Yang Zhou, Qianmeng Lin, Ying Fu, Raquel Ortega, Xiaojing Lin, Zhengchao Tu, Adam V. Patterson, Jeff B. Smaill*, Yongheng Chen*, and Xiaoyun Lu*. Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4. J. Med. Chem. 2022, 65, 5113−5133\r
\r
Xiaoyun Lu*, Jeff B Smaill, Adam V Patterson, Ke Ding. Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors. J Med Chem. 2022, 65, 58-83.\r
\r
Fang Yang, Yalei Wen, Chaofan Wang, Yuee Zhou, Yang Zhou, Zhi-Min Zhang, Tongzheng Liu*, Xiaoyun Lu*. Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC. Eur J Med Chem. 2022, 230, 114088.\r
\r
Zuqin Wang, Ting Ran, Fang Xu, Chang Wen, Shukai Song, Yang Zhou*, Hongming Chen*, Xiaoyun Lu*. Deep learning-driven scaffold hopping in the discovery of Akt kinase inhibitors. Chem Commun (Camb). 2021, 57, 10588-10591.\r
\r
Liang Jiang, Yuting Wang, Qian Li, Zhengchao Tu, Sihua Zhu, Sanfang Tu*, Zhang Zhang*, Ke Ding*, Xiaoyun Lu*. Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation. Acta Pharm Sin B. 2021, 11, 315-1328.\r
\r
Xiaoyun Lu*, Jeff B. Smaill, Ke Ding*, Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. J Med. Chem. 2020, 63, 19, 10726–10741.\r
\r
Xiaoyun Lu*, Jeff B. Smaill, and Ke Ding*, New Promise and Opportunities for Allosteric Kinase Inhibitors. Angew. Chem. Int. Edit., 2020, 59, 13764-13776.\r
\r
Jianzhang Yang, Marthandam Asokan Shibu, Lulu Kong, Jinfeng Luo, Farheen BadrealamKhan, Yanhui Huang, Zheng-Chao Tu, Cai-Hong Yun, Chih-Yang Huang, Ke Ding*, Xiaoyun Lu*.Design, Synthesis and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as new Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors. J. Med. Chem. 2020, 63, 2114-2130.